Medinice

Medinice ROIC

The Return on Invested Capital (ROIC) of Medinice (ICE.WA) as of Oct 31, 2026 is -7.60 %. In the previous year, Return on Invested Capital (ROIC) was 46.19 % — a change of -116.45% (lower).

ROIC

-7.60 %

YoY

-116.45%

Last updated:

Return on Invested Capital (ROIC) of Medinice is 2025 -7.60 % . Return on Invested Capital (ROIC) of Medinice was 2024 46.19 % . It decreases by -116.45% lower compared to the previous year.

The Medinice ROIC history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROIC
Date
ROIC
Jan 1, 2018
-53.95 PLN
Jan 1, 2019
-25.72 PLN
Jan 1, 2020
-17.43 PLN
Jan 1, 2021
-6.97 PLN
Jan 1, 2022
-13.06 PLN
Jan 1, 2023
-15.06 PLN
Jan 1, 2024
46.19 PLN
Jan 1, 2025
-7.60 PLN
The Medinice ROIC history
YEARROICYoY
-7.60 %-116.45%
46.19 %-406.64%
-15.06 %+15.33%
-13.06 %+87.29%
-6.97 %-60.00%
-17.43 %-32.21%
-25.72 %-52.33%
-53.95 %+260.78%
-14.95 %-82.68%
-86.34 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medinice Stock analysis

What does Medinice do? Medinice SA generates revenue through the commercialization of medical device solutions, primarily focusing on cardiological and cardiosurgical products. The company's portfolio includes CathAIO, Cryoapplicator, Med-IConsole, Minimax, and Pacepress, which are sold globally via licensing agreements. These products target healthcare providers and medical device manufacturers seeking minimally invasive cardiology solutions. The firm collaborates with research centers in Poland and Europe to develop and commercialize inventions from its co-founders and acquired projects, emphasizing safe and minimally invasive medical technologies. Medinice SA's business model revolves around licensing its proprietary technologies to international partners for the production of medical devices. The company leverages its global potential projects to secure worldwide distribution agreements, ensuring revenue streams from multiple markets. By specializing in cardiology and cardio surgery, Medinice SA positions itself as a provider of innovative solutions for healthcare systems seeking advanced, minimally invasive procedures. The firm's revenue is derived from licensing fees and sales of its medical device solutions, with a focus on cardiological and cardiosurgical applications. Its products, such as CathAIO and Cryoapplicator, are designed to meet global demand for safe and minimally invasive treatments. Medinice SA's strategy involves partnering with research centers in Poland and Europe to enhance its portfolio, ensuring continuous innovation and market relevance in the medical device sector. Medinice is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medinice stock

Return on Invested Capital (ROIC) of Medinice is -7.60 % in 2025.

Return on Invested Capital (ROIC) of Medinice changed from 46.19 % to -7.60 %, representing a -116.45% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Invested Capital (ROIC) Medinice since 2006 – with annual values, charts, and detailed analysis.

ROIC measures how effectively a company uses its invested capital to generate profits. A ROIC above the cost of capital creates shareholder value.

ROIC = NOPAT / Invested Capital

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Invested Capital (ROIC)'s Medinice with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Invested Capital (ROIC)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Invested Capital (ROIC).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — Medinice

All Key Metrics — Medinice